Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499500 | 0.88 | CYP19A1 (0.33) | CYP19A1FNTAFNTBS1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL5891928 | 0.87 | S1PR1 (0.33) | CYP19A1FNTAFNTBS1PR1S1PR3 | |
| SCHEMBL8156634 | 0.84 | S1PR1 (0.33) | CYP19A1S1PR1S1PR3EGLN1 | |
| Hydrochloric Acid SCHEMBL8148673 | 0.83 | S1PR1 (0.33) | CYP19A1S1PR1S1PR3EGLN1 | |
| SCHEMBL8149818 | 0.76 | EGLN1 (0.35) | CYP19A1EGLN1 | |
| SCHEMBL8156266 | 0.74 | CYP11B1 (0.41) | CYP19A1FNTAFNTB | |
| SCHEMBL8141879 | 0.74 | CYP11B1 (0.40) | CYP19A1FNTAFNTB | |
| SCHEMBL3501968 | 0.73 | CYP19A1 (0.36) | CYP19A1EGLN1 | |
| SCHEMBL8157295 | 0.73 | EGLN1 (0.33) | CYP19A1EGLN1 | |
| SCHEMBL8149670 | 0.73 | CYP11B1 (0.41) | CYP19A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |